About OvaScience
OvaScience is a company based in Waltham (United States) founded in 2011. OvaScience has raised $76.94 million across 3 funding rounds from investors including RA Capital, General Catalyst and Cycad Group. The company has 19 employees as of December 31, 2022. OvaScience offers products and services including IDN Poker, Ceme Online, Dominoqq, and Super10. OvaScience operates in a competitive market with competitors including Tenaya Therapeutics, Athira Pharma, Orca Bio, Avita Medical and Tune Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 19 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tempest Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$76.94 M (USD)
in 3 rounds
-
Latest Funding Round
$35 M (USD), Series B
Mar 26, 2013
-
Investors
RA Capital
& 3 more
-
Employee Count
19
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OvaScience
OvaScience offers a comprehensive portfolio of products and services, including IDN Poker, Ceme Online, Dominoqq, and Super10.
Platform for playing poker games with strategic betting.
Service for domino-based card games and multiplayer wagering.
Platform offering domino games with competitive online play.
Game for strategic card combinations and player betting.
People of OvaScience
Unlock access to complete
Unlock access to complete
Funding Insights of OvaScience
OvaScience has successfully raised a total of $76.94M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $35 million completed in March 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OvaScience
OvaScience has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, General Catalyst and Cycad Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and transformation services for entrepreneurs in technology and finance sectors.
|
Locked | Locked | Locked | |
|
Stage agnostic VC firm investing primarily in the US
|
Locked | Locked | Locked | |
|
Investments are directed toward young firms in pharmaceuticals and biotech.
|
Locked | Locked | Locked |
Investor details for OvaScience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OvaScience
Investment portfolio details for OvaScience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OvaScience
Detailed financials for OvaScience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ovascience Comparisons
Peer comparison for OvaScience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OvaScience
OvaScience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Athira Pharma, Orca Bio, Avita Medical and Tune Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapeutics, including for Alzheimer’s and Parkinson’s, are developed.
|
|
| Locked | Locked | Locked |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| Locked | Locked | Locked |
Cell and gene therapies are developed via an epigenomic platform.
|
|
| Locked | Locked | Locked |
Drugs for hypoactive sexual desire disorder in women are developed.
|
Detailed competitors of OvaScience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ovascience
Complete news archive for OvaScience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OvaScience
OvaScience was founded in 2011 and raised its 1st funding round 1 year after it was founded.
OvaScience is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Chris Kroeger is the current CEO of OvaScience.
OvaScience is a funded company, having raised a total of $76.94M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at OvaScience is 19.
Developer of new fertility treatments for women. The treatment is based on its proprietary technology platform that leverages the discovery of egg precursor (EggPC) cells immature egg cells found inside the protective ovarian lining. The AUGMENT treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. Also has OvaPrime program, which could increase a womans egg reserve, and is developing the OvaTure treatment, an IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S.
OvaScience's top competitors include Tenaya Therapeutics, Athira Pharma and Orca Bio.
OvaScience offers IDN Poker, Ceme Online, Dominoqq, and Super10.
OvaScience has 4 investors. Key investors include RA Capital, General Catalyst, Cycad Group, and Hunt BioVentures.